Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 Studies

Lang Wu, Jingjing Zhu, Larry J. Prokop, Mohammad H Murad

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Different anti-diabetic medications (ADMs) may modify cancer risk and mortality in patients with diabetes. We conducted a systematic review and meta-analysis to estimate the magnitude of association and quality of supporting evidence for each ADM. A total of 265 studies (44 cohort studies, 39 case-control studies, and 182 randomized controlled trials (RCT)) were identified, involving approximately 7.6 million and 137,540 patients with diabetes for observational studies and RCTs, respectively. The risk of bias overall was moderate. Meta-analysis demonstrated that the use of metformin or thiazolidinediones was associated with a lower risk of cancer incidence (RR = 0.86, 95% CI 0.83-0.90, I<sup>2</sup> = 88.61%; RR = 0.93, 95% CI 0.91-0.96, I<sup>2</sup> = 0.00% respectively). On the other hand, insulin, sulfonylureas and alpha glucosidase inhibitor use was associated with an increased risk of cancer incidence (RR = 1.21, 95% CI 1.08-1.36, I<sup>2</sup> = 96.31%; RR = 1.20, 95% CI 1.13-1.27, I<sup>2</sup> = 95.02%; RR = 1.10, 95% CI 1.05-1.15, I<sup>2</sup> = 0.00% respectively). Use of other types of ADMs was not significantly associated with cancer risk. This study indicates that some ADMs may modify the risk of cancer in individuals with diabetes. Knowledge of this risk may affect the choice of ADM in individuals concerned about cancer or at increased risk for cancer.

Original languageEnglish (US)
Article number10147
JournalScientific Reports
Volume5
DOIs
StatePublished - Jun 15 2015

Fingerprint

Meta-Analysis
Mortality
Neoplasms
Therapeutics
Thiazolidinediones
Metformin
Incidence
Observational Studies
Case-Control Studies
Cohort Studies
Randomized Controlled Trials
Insulin

ASJC Scopus subject areas

  • General

Cite this

Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality : A Meta-Analysis of 265 Studies. / Wu, Lang; Zhu, Jingjing; Prokop, Larry J.; Murad, Mohammad H.

In: Scientific Reports, Vol. 5, 10147, 15.06.2015.

Research output: Contribution to journalArticle

@article{4cec30acf52d47bfb23304daee96f10a,
title = "Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 Studies",
abstract = "Different anti-diabetic medications (ADMs) may modify cancer risk and mortality in patients with diabetes. We conducted a systematic review and meta-analysis to estimate the magnitude of association and quality of supporting evidence for each ADM. A total of 265 studies (44 cohort studies, 39 case-control studies, and 182 randomized controlled trials (RCT)) were identified, involving approximately 7.6 million and 137,540 patients with diabetes for observational studies and RCTs, respectively. The risk of bias overall was moderate. Meta-analysis demonstrated that the use of metformin or thiazolidinediones was associated with a lower risk of cancer incidence (RR = 0.86, 95{\%} CI 0.83-0.90, I2 = 88.61{\%}; RR = 0.93, 95{\%} CI 0.91-0.96, I2 = 0.00{\%} respectively). On the other hand, insulin, sulfonylureas and alpha glucosidase inhibitor use was associated with an increased risk of cancer incidence (RR = 1.21, 95{\%} CI 1.08-1.36, I2 = 96.31{\%}; RR = 1.20, 95{\%} CI 1.13-1.27, I2 = 95.02{\%}; RR = 1.10, 95{\%} CI 1.05-1.15, I2 = 0.00{\%} respectively). Use of other types of ADMs was not significantly associated with cancer risk. This study indicates that some ADMs may modify the risk of cancer in individuals with diabetes. Knowledge of this risk may affect the choice of ADM in individuals concerned about cancer or at increased risk for cancer.",
author = "Lang Wu and Jingjing Zhu and Prokop, {Larry J.} and Murad, {Mohammad H}",
year = "2015",
month = "6",
day = "15",
doi = "10.1038/srep10147",
language = "English (US)",
volume = "5",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality

T2 - A Meta-Analysis of 265 Studies

AU - Wu, Lang

AU - Zhu, Jingjing

AU - Prokop, Larry J.

AU - Murad, Mohammad H

PY - 2015/6/15

Y1 - 2015/6/15

N2 - Different anti-diabetic medications (ADMs) may modify cancer risk and mortality in patients with diabetes. We conducted a systematic review and meta-analysis to estimate the magnitude of association and quality of supporting evidence for each ADM. A total of 265 studies (44 cohort studies, 39 case-control studies, and 182 randomized controlled trials (RCT)) were identified, involving approximately 7.6 million and 137,540 patients with diabetes for observational studies and RCTs, respectively. The risk of bias overall was moderate. Meta-analysis demonstrated that the use of metformin or thiazolidinediones was associated with a lower risk of cancer incidence (RR = 0.86, 95% CI 0.83-0.90, I2 = 88.61%; RR = 0.93, 95% CI 0.91-0.96, I2 = 0.00% respectively). On the other hand, insulin, sulfonylureas and alpha glucosidase inhibitor use was associated with an increased risk of cancer incidence (RR = 1.21, 95% CI 1.08-1.36, I2 = 96.31%; RR = 1.20, 95% CI 1.13-1.27, I2 = 95.02%; RR = 1.10, 95% CI 1.05-1.15, I2 = 0.00% respectively). Use of other types of ADMs was not significantly associated with cancer risk. This study indicates that some ADMs may modify the risk of cancer in individuals with diabetes. Knowledge of this risk may affect the choice of ADM in individuals concerned about cancer or at increased risk for cancer.

AB - Different anti-diabetic medications (ADMs) may modify cancer risk and mortality in patients with diabetes. We conducted a systematic review and meta-analysis to estimate the magnitude of association and quality of supporting evidence for each ADM. A total of 265 studies (44 cohort studies, 39 case-control studies, and 182 randomized controlled trials (RCT)) were identified, involving approximately 7.6 million and 137,540 patients with diabetes for observational studies and RCTs, respectively. The risk of bias overall was moderate. Meta-analysis demonstrated that the use of metformin or thiazolidinediones was associated with a lower risk of cancer incidence (RR = 0.86, 95% CI 0.83-0.90, I2 = 88.61%; RR = 0.93, 95% CI 0.91-0.96, I2 = 0.00% respectively). On the other hand, insulin, sulfonylureas and alpha glucosidase inhibitor use was associated with an increased risk of cancer incidence (RR = 1.21, 95% CI 1.08-1.36, I2 = 96.31%; RR = 1.20, 95% CI 1.13-1.27, I2 = 95.02%; RR = 1.10, 95% CI 1.05-1.15, I2 = 0.00% respectively). Use of other types of ADMs was not significantly associated with cancer risk. This study indicates that some ADMs may modify the risk of cancer in individuals with diabetes. Knowledge of this risk may affect the choice of ADM in individuals concerned about cancer or at increased risk for cancer.

UR - http://www.scopus.com/inward/record.url?scp=84935873481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84935873481&partnerID=8YFLogxK

U2 - 10.1038/srep10147

DO - 10.1038/srep10147

M3 - Article

C2 - 26076034

AN - SCOPUS:84935873481

VL - 5

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 10147

ER -